• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Policy on anti-corruption, gifts and hospitality
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
XVIVO
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Policy on anti-corruption, gifts and hospitality
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error

2020

  • Delårsrapport januari-juni 2020

  • Interim report January - June 2020

  • Delårsrapport Januari - Mars 2020

  • Interim Report January - March 2020

2019

  • Bokslutskommuniké 2019

  • Report on Operations 2019

  • Delårsrapport Januari - September 2019

  • Interim Report January - September 2019

  • Delårsrapport Januari - Juni 2019

  • Interim Report January - June 2019

  • Delårsrapport Januari - Mars 2019

  • Interim Report January - March 2019

2018

  • Bokslutskommuniké 2018

  • Report on Operations 2018

  • Delårsrapport Januari - September 2018

  • Interim Report January - September 2018

  • Delårsrapport Januari - Juni 2018

  • Interim Report January - June 2018

  • Delårsrapport Januari - Mars 2018

  • Interim Report January - March 2018

2017

  • Bokslutskommuniké 2017

  • Report on Operations 2017

  • Delårsrapport Januari - September 2017

  • Interim report January - September 2017

  • Delårsrapport Januari - Juni 2017

  • Interim report January - June 2017

  • Delårsrapport Januari - Mars 2017

  • Interim report January - March 2017

2016

  • Bokslutskommuniké 2016

  • Report on Operations 2016

  • Delårsrapport Januari - September 2016

  • Interim report January - September 2016

  • Delårsrapport Januari - Juni 2016

  • Interim report January - June 2016

  • Delårsrapport Januari - Mars 2016

  • Interim report January - March 2016

2015

  • Delårsrapport januari – mars 2015

  • Interim Report January – March 2015

  • Delårsrapport januari-juni 2015

  • Interim report January – June 2015

  • Delårsrapport januari-september 2015

  • Interim report January – September 2015

  • Bokslutskommuniké 2015

  • Report on Operations 2015

2014

  • Delårsrapport januari – mars 2014

  • Interim Report January – March 2014

  • Delårsrapport januari – juni 2014

  • Interim Report January – June 2014

  • Delårsrapport januari – september 2014

  • Interim Report January – September 2014

  • Bokslutskommuniké 2014

  • Report on Operations 2014

2013

  • Delårsrapport januari – mars 2013

  • Interim report January – March 2013

  • Delårsrapport januari – juni 2013

  • Interim report January – June 2013

  • Delårsrapport januari-september 2013

  • Interim report January-September 2013

  • Bokslutskommuniké 2013

  • Report on operations 2013

2012

  • Bokslutskommuniké 2012

  • Report on operations 2012

About us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on three continents. The company is listed on Nasdaq.

Contact

Visiting address:
Swedish Office
XVIVO Perfusion AB
Entreprenörsstråket 10
431 53 Mölndal
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivogroup.com

 

Report a violations or breach here: Whistleblower

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2026 XVIVO. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO. Read more about Cookies

Approve